Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K
2022 FY
Annual report
24 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
22 Aug 22
Current reports
8-K
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
6 Jun 24
8-K
Regulation FD Disclosure
4 Jun 24
8-K
Regulation FD Disclosure
3 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
29 May 24
8-K
Other Events
15 May 24
8-K
Regulation FD Disclosure
7 May 24
8-K
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
MAIA Biotechnology Announces $1.33 Million Private Placement
26 Mar 24
8-K
Other Events
25 Mar 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
15 May 24
S-8
Registration of securities for employees
19 Apr 24
424B5
Prospectus supplement for primary offering
25 Mar 24
D
$5.70 mm in equity / options / securities to be acquired, sold $2.92 mm, 19 investors
21 Mar 24
424B5
Prospectus supplement for primary offering
14 Feb 24
D
$4.86 mm in equity / options / securities to be acquired, sold $4.86 mm, 3 investors
29 Nov 23
424B5
Prospectus supplement for primary offering
17 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
424B5
Prospectus supplement for primary offering
1 Sep 23
S-3
Shelf registration
14 Aug 23
Proxies
Other
EFFECT
Notice of effectiveness
24 Aug 23
CORRESP
Correspondence with SEC
21 Aug 23
UPLOAD
Letter from SEC
18 Aug 23
EFFECT
Notice of effectiveness
25 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
CORRESP
Correspondence with SEC
21 Apr 23
CORRESP
Correspondence with SEC
18 Apr 23
CORRESP
Correspondence with SEC
18 Apr 23